Targets › APEX1
1 program from 1 company in 2 trials: 1 Phase 2, 1 Phase 1; Oncology; next expected readout Jun 2027.
Multifunctional protein that plays a central role in the cellular response to oxidative stress. The two major activities of APEX1 are DNA repair and redox regulation of transcriptional factors. (UniProt, P27695)
Open in Phaseline: the race on APEX1, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| National Cancer Institute (NCI) | Methoxyamine Base excision repair (BER) pathway inhibitor; enhances chemotherapy sensitivity by blockin | APEX1 | Phase 2 | Lung Adenocarcinoma; Advanced Malignant Solid Neoplasm | Jun 2027 |
Lung Adenocarcinoma (1) Advanced Malignant Solid Neoplasm (1)
mixed (1)
National Cancer Institute (NCI) (1)
–
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.